How much loss to follow-up is acceptable in long-term randomised trials and prospective studies?

How much loss to follow-up is acceptable in long-term randomised trials and prospective studies?

vor 18 Jahren
0
0 0
Podcast
Podcaster

Beschreibung

vor 18 Jahren

Weitere Episoden

Report of the Working Group `Overall Blood Supply Strategy with Regard to Variant Creutzfeldt-Jakob Disease (vCJD)'

Report of the Working Group `Overall Blood Supply Strategy with Regard to Variant Creutzfeldt-Jakob Disease (vCJD)'

vor 17 Jahren
Intranasal insulin to improve developmental delay in children with 22q13 deletion syndrome: an exploratory clinical trial

Intranasal insulin to improve developmental delay in children with 22q13 deletion syndrome: an exploratory clinical trial

vor 17 Jahren
Guidelines for initiation of anti-tumour necrosis factor therapy in rheumatoid arthritis: similarities and differences across Europe.

Guidelines for initiation of anti-tumour necrosis factor therapy in rheumatoid arthritis: similarities and differences across Europe.

vor 17 Jahren
JNK inhibition sensitises hepatocellular carcinoma cells but not normal hepatocytes to the TNF-related apoptosis-inducing ligand.

JNK inhibition sensitises hepatocellular carcinoma cells but not normal hepatocytes to the TNF-related apoptosis-inducing ligand.

vor 17 Jahren
Influence of peptidylarginine deiminase type 4 genotype and shared epitope on clinical characteristics and autoantibody profile of rheumatoid arthritis.

Influence of peptidylarginine deiminase type 4 genotype and shared epitope on clinical characteristics and autoantibody profile of rheumatoid arthritis.

vor 17 Jahren
In Podcasts werben
Schalte jetzt Werbung in Podcasts.
Alle Episoden anzeigen

Abonnenten

Logo
15
15
Episode teilen
How much loss to follow-up is acceptable in long-term randomised trials and prospective studies?
How much loss to follow-up is acceptable in long-term randomised trials and prospective studies?
Close